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Abstract
As a devastating Ebola outbreak in West Africa continues, non-pharmaceutical control mea-
sures including contact tracing, quarantine, and case isolation are being implemented. In
addition, public health agencies are scaling up efforts to test and deploy candidate vac-
cines. Given the experimental nature and limited initial supplies of vaccines, a mass vacci-
nation campaign might not be feasible. However, ring vaccination of likely case contacts
could provide an effective alternative in distributing the vaccine. To evaluate ring vaccina-
tion as a strategy for eliminating Ebola, we developed a pair approximation model of Ebola
transmission, parameterized by confirmed incidence data from June 2014 to January 2015
in Liberia and Sierra Leone. Our results suggest that if a combined intervention of case iso-
lation and ring vaccination had been initiated in the early fall of 2014, up to an additional 126
cases in Liberia and 560 cases in Sierra Leone could have been averted beyond case isola-
tion alone. The marginal benefit of ring vaccination is predicted to be greatest in settings
where there are more contacts per individual, greater clustering among individuals, when
contact tracing has low efficacy or vaccination confers post-exposure protection. In such
settings, ring vaccination can avert up to an additional 8% of Ebola cases. Accordingly, ring
vaccination is predicted to offer a moderately beneficial supplement to ongoing non-phar-
maceutical Ebola control efforts.
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Author Summary
Public health efforts for controlling the 2014–2015 Ebola outbreak in West Africa have fo-
cused on contact tracing and isolation of symptomatic individuals. In addition, substantial
resources have been committed to scaling up the production of experimental vaccines.
Ring vaccination—the vaccination of the contacts of an infected individual—was success-
fully implemented to achieve smallpox eradication. Ring vaccination is particularly feasible
and effective in settings where the supply of vaccines is limited and disease incidence is
low. Using a disease transmission model, we evaluated the benefit of adding ring vaccina-
tion to case isolation in Liberia and Sierra Leone. We found that ring vaccination could
have averted up to 126 cases in Liberia and 560 cases in Sierra Leone, thereby saving lives
and intervention resources.
Introduction
The Ebola outbreak in West Africa has resulted in unprecedented morbidity and mortality. As
of March 4 2015, the World Health Organization (WHO) had reported 23,914 cases and 9,792
fatalities in countries with widespread transmission [1], with Liberia and Sierra Leone having
been most profoundly impacted.
Ebola transmission occurs via direct human-to-human contact with body fluids from symp-
tomatic patients. An elevated viral load in late-stage symptomatic or deceased victims can also
put family members and funeral attendees at risk of post-mortem disease transmission [2, 3].
The health ministries in Liberia and Sierra Leone have been implementing intensive contact-
tracing procedures, where patients or their relatives are interviewed to identify people with
whom they came into close contact after developing symptoms. Contacts who are healthy but
might have been exposed are monitored for 21 days, the maximum duration of the Ebola incu-
bation period [4]. Contacts who present with Ebola symptoms, such as fever, are transported
to isolation clinics [5]. Given that Ebola is transmitted directly between close contacts, the so-
cial clustering of individuals can be fundamental to the success of intervention strategies [6–8].
Several Ebola vaccine candidates have been developed in the past decade [9, 10], some of
which have already been found to be safe and immunogenic in Phase 1 clinical trials [11]. One
of these, a recombinant vesicular stomatitis viruses (rVSV) vaccine, conferred protection to
non-human primates when administered immediately following exposure to an otherwise le-
thal dose of Ebola virus [12]. An alternate vaccine formula based on the chimpanzee adenovi-
rus type 3 (ChAd3), developed in partnership between the National Institute of Allergy and
Infectious Disease and GlaxoSmithKline, together with the rVSV vaccine are currently entering
Phase 2/3 clinical trials in West Africa [13]. In addition, the WHO has deemed it ethical to use
experimental vaccines in the current Ebola emergency situation [14].
Even with the scale up in production [15], the supply would be insufficient for mass vacci-
nation of affected countries, given a combined population of over twenty million people. Con-
sequently, the judicious prioritization of vaccine recipients is essential to maximize vaccine
impact. Aside from vaccinating healthcare workers who are at high occupational risk of con-
tracting Ebola [16, 17], a vaccination strategy to reduce community-wide transmission has yet
to be evaluated. Evaluating Ebola vaccination strategies is pertinent not only to the current epi-
demic, but also in mitigating future outbreaks.
The targeting of the exposed contacts of infected individuals, a strategy known as ring vacci-
nation [18, 19], is efficient for controlling rare pathogens [20]. For example, ring vaccination
proved to be an effective strategy for smallpox eradication [18, 19]. Furthermore, ring
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vaccination could be seamlessly incorporated into the contact tracing efforts underway in the
affected countries.
To evaluate the effectiveness of Ebola ring vaccination in West Africa, we developed a math-
ematical model that approximates disease progression in a realistic contact network. We pre-
dicted that the marginal benefit was greatest in settings where there are more contacts per
individual, greater clustering, or insufficient resources for effective contact tracing. However,
we found that ring vaccination provides moderate marginal benefit beyond current non-
pharmaceutical interventions.
Methods
Ebola transmission model
To determine the effectiveness of ring vaccination and case isolation of Ebola in West Africa,
we modeled the transmission between close contacts by using the pair-approximation method-
ology which simulates disease propagation through a network (Fig 1, S1 Text) [6, 21]. Specifi-
cally, we tracked both the number of susceptible individuals ([S]), latently infected individuals
([E]), infectious individuals ([I]), removed individuals ([R]), as well as the number of contacts
between epidemiological states. For example, [SI] denotes the number of contacts between sus-
ceptible and infectious individuals. We denoted the average number of contacts per individual
in the network by k. To account for empirical mixing patterns between individuals during the
Ebola outbreak in West Africa [22], we considered clustering of individuals. Clustering can be
Fig 1. A) Our dynamic model is driven by the spatial correlation of individuals in the population. New latent infections depend on the connections
between susceptible and infectious individuals (red). Case isolation and ring vaccination depend on the connections between individuals in the general
population (i.e. S, E, and I) and those in isolation (TI and TR) (blue). B)-D) Examples of networks with an average of 5.5 contacts per individual (approximating
the 5.74 estimate from Liberia [22]) and clustering coefficients of B) 0.10, C) 0.21, and D) 0.40.
doi:10.1371/journal.pntd.0003794.g001
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defined as the extent to which individuals who are in contact with each other share other con-
tacts in the network and is quantified by the clustering coefficient (ϕ).
A susceptible individual becomes latently infected (E) at rate β[SI] per day, where β is the
transmission rate. An individual remains in the latent period for an average duration of 1/σ
days until becoming symptomatic and infectious (I). An infectious individual will transition to
the removed state (R) (i.e. recovered or deceased) at rate δ, where 1/δ days is the average dura-
tion of the infectious period. In addition, we incorporated case isolation by removing a percent-
age of infectious individuals (ψ) from the community at rate γ per day (Table 1).
For our base case analysis, we used k = 5.74 as the mean number of contacts and ϕ = 0.21 for
the clustering coefficient, derived from contact tracing data collected by the Liberian Ministry of
Health and Social Welfare [22]. We also considered clustering coefficients of 0.10 and 0.40
(Table 1), consistent with previous studies on human contact networks [23–26]. In addition, we
accounted for possible under-reporting of contacts by considering higher values of k (Table 1).
Contact tracing and case isolation
During contact tracing, an infected contact in the latent period moves to the observed state
(TE) while a contact in the symptomatic period enters the isolated state (TI) at a daily contact
tracing rate of τ per isolated case. Once an isolated individual has recovered and is no longer in-
fectious, they transition to the TR state (S1 Text), while the individuals contacts are followed
for an additional 1/ω days (Table 1). We defined the contact tracing efficacy by the probability
of identifying an infected individual before transmission occurs (τ/(τ+ν)), where 1/ν is the aver-
age serial interval (Table 1). We assumed that the base case contact tracing efficacy was 40%,
consistent with empirical estimates [27, 28]. We deemed the current Ebola epidemic to be elim-
inated at the point where incidence became lower than 0.025 cases per day, which corresponds
to no new cases over a 42 day period [29].
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Ring vaccination
We assumed that a proportion of the contacts of isolated cases identified through contact trac-
ing are vaccinated. Experimental studies indicate that several vaccine candidates facilitate re-
covery of latent infection in non-human primates if administered within two days post-
infection [12, 30]. We used a vaccine efficacy (ε) of 100% as our base case scenario and consid-
er a range of vaccine efficacies from 5% to 95% (S1 Text). We investigated two scenarios: 1)
vaccination must be administered pre-exposure in order to confer protection such that only
susceptible individuals (S) who are uninfected can be protectively vaccinated, and 2) vaccina-
tion is efficacious with both pre- and post-exposure administration such that vaccine protec-
tion can be conferred to individuals in both the susceptible (S) and latently infected (E) [30].
The use of a post-exposure vaccine in the equations below is represented by χ = 1, otherwise χ
= 0. Susceptible and latently infected individuals are vaccinated at the same daily contact trac-
ing rate τ per isolated individual (S1 Text). When a susceptible individual is vaccinated they
Table 1. Epidemiological parameters used in dynamic model.
Parameter Description (unit) Value (SA Value) Reference
N Population size of Liberia 4,092,310 [51]
N Population size of Sierra Leone 6,348,350 [52]
1/δ Average duration of infectious period (days) 12 [53–55]
1/σ Average duration of latent period (days) 9 [53, 56]
ϕ Clustering coefﬁcient 0.21 (0.10 and 0.40) [22–24]
k Average number of contacts 5.74 (10) [22]
E0 Initial number of exposed individuals 2 (Liberia)
14 (Sierra Leone) [57]
1/ω The duration of follow up of contacts (days) 21 [58]
1/ν The average serial interval (days) 15 [53, 55]
1/υ The average time to vaccine acquired immunity (days) 14 [59–62]
1/γ The average number of days until infected individuals enter isolation (days) 5 [53, 63]
Ψ The fraction of infected individuals that enter isolation 80% [53, 63]
c ¼ Cdð1CÞgþCd 0.625 [64]
doi:10.1371/journal.pntd.0003794.t001
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remain unprotected (P) until vaccine-mediated immunity is acquired 1/υ days later.
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Epidemiological data and parameter estimates
To account for the recent decline in Ebola incidence [31, 32], we used a piecewise approach to
calibrate our model, fitting both the early growth phase of the epidemic and the later phase of
reduced transmission (S1 Fig, S1 Table, S1 Text). We estimated the rate of transmission per in-
fectious contact (β), the date of Ebola emergence into the population (t0), the initiation of inter-
vention scale up (tS), and reduced transmission mediated by factors other than intervention,
such as behavior change (ξ). From the date of intervention scale up, we assumed that case isola-
tion was implemented at our base case contact tracing efficacy. Using a least squares fitting al-
gorithm, we estimated these four parameters from weekly confirmed incidence data in Liberia
and Sierra Leone, respectively (S1 Table and S1 Text). We fit the model to confirmed incidence
data from June 8, 2014 to January 4, 2015 for Liberia [31] and fromMay 11, 2014 to January 4,
2015 for Sierra Leone [32] (S1 Table and S1 Text). However, on December 20, 2014, the
deployment of international aid began in Sierra Leone and considerably reduced transmission
[33–35]. Thus, we considered a second reduction in transmission from this time point (S1
Text). To validate the calibration of Liberia and Sierra Leone, we forecasted the incidence of
Ebola to March 8, 2015 and calculated the correlation fit value to the observed incidence (S1
Fig, S1 Table).
Results
Base case analysis
We estimated that intervention efforts were initially scaled up on September 5, 2014 in Liberia
and October 8, 2014 in Sierra Leone. Our model predicts that under status quo intervention
the total number of confirmed Ebola cases in Liberia will be 3,899 cases and 10,425 cases in Si-
erra Leone (Fig 2). If ring vaccination using a prophylactic vaccine had been combined with
the initial scaling up of non-pharmaceutical interventions, four additional cases could have
been averted in Liberia and 36 cases could have been averted in Sierra Leone, corresponding to
Harnessing Case Isolation and Ring Vaccination to Control Ebola
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003794 May 29, 2015 6 / 13
relatively low marginal benefits of 0.21% and 0.48% additional cases averted, respectively (S2
Fig). By contrast, for a vaccine that can confer post-exposure protection, we estimate that 107
cases could have been averted in Liberia and 477 cases could be averted in Sierra Leone (Fig 2),
corresponding to marginal benefits of 4.7% and 6.5%, respectively (S3 Fig).
We found that a prophylactic vaccine had minimal impact on the number of symptomatic
individuals identified by contact tracing (S4 Fig). However, if the vaccine confers post-exposure
protection, then ring vaccination is predicted to reduce the number of symptomatic individuals
identified by contact tracing by 40 in Liberia and 137 in Sierra Leone compared to case isola-
tion alone, thereby reducing requirements of isolation units in hospitals (S4 Fig).
Sensitivity analysis
We conducted sensitivity analysis with respect to contact tracing efficacy, average number of
contacts per individuals (k), and the clustering coefficient (ϕ) (S2 Text). Varying contact trac-
ing efficacy from 5% to 50%, the predicted epidemic size without ring vaccination ranged from
3,874 to 3,988 confirmed cases in Liberia and 10,246 to 11,048 confirmed cases in Sierra Leone
(Fig 2). Implementing ring vaccination with a prophylactic vaccine is expected to achieve the
greatest marginal benefit when contact tracing efficacies are between 20% and 28% in both Li-
beria and Sierra Leone (S2 Fig, S2 Text). Specifically, the greatest marginal benefit of ring vacci-
nation can be up to 0.29% in Liberia and up to 0.64% in Sierra Leone, depending on the
vaccine efficacy (S2 Fig). However, a vaccine with post-exposure protection is estimated to
Fig 2. The estimated total number of confirmed cases for various contact tracing and vaccine efficacies in (A)-B)) Liberia and (C)-D)) Sierra Leone
using (A), C)) a prophylactic vaccine and (B), D)) a vaccine that confers post-exposure protection. The model was fit using k = 5.74 with a clustering
coefficient of ϕ = 0.21, as estimated for Liberia [22]. A vaccine efficacy of zero would correspond to the implementation of case isolation only.
doi:10.1371/journal.pntd.0003794.g002
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provide up to 6%marginal benefit in Liberia and 8% in Sierra Leone (S2 Text, S3 Fig). These re-
sults suggest that ring vaccination provides moderate benefit to case isolation under a range of
contact tracing efficacies and vaccine efficacies.
Our sensitivity analysis of the social mixing patterns (k and ϕ) show that the marginal bene-
fit of adding ring vaccination rises with more contacts per individual or increasing clustering
(S2 and S5 Figs, S2 Text).
Discussion
We demonstrated that a combination of contact tracing, case isolation and ring vaccination
could effectively reduce Ebola transmission. In Liberia, as well as in past Ebola outbreaks, im-
plementing case isolation along with change in human behavior dramatically reduced trans-
mission [36–39], which commonly occurs when people perceive infection risk associated with
specific behaviors. Our results suggest that in this current context of reduced transmission,
ring vaccination offers only moderate additional benefit, which is consistent with findings
from a previous cholera model [40]. Although the incremental benefit of ring vaccination
could be relatively moderate, the marginal benefit of ring vaccination is expected to increase
with the average number of contacts per individual, the clustering coefficient or lower contact
tracing efficacies. Therefore, ring vaccination is particularly useful in regions where contact
tracing is logistically challenging. In addition, a vaccine that can confer post-exposure efficacy
is much more effective for use in ring vaccination strategies than a vaccine that can only confer
protection prophylactically. An additional benefit of ring vaccination that is more pronounced
for a vaccine that confers post-exposure protection than for an exclusively prophylactic vaccine
is the reduction in the number of symptomatic individuals who need hospitalization.
The 2014 Ebola outbreak in West Africa has affected both rural and urban communities
[41], which differ in accessibility for contact tracing and hospital facilities for case isolation.
There is also regional variation in the number and clustering of contacts [42]. Our analysis
demonstrates that the benefit of adding ring vaccination to case isolation is influenced by the
extent of clustering in a population. Specifically, we found ring vaccination provided the great-
est marginal benefit to case isolation in highly clustered populations, such as crowded homes
or schools [23–26, 43]. As social networks can be highly complex systems consisting of densely
connected communities [44–46], future studies should evaluate not only transmission patterns
within communities but also transmission patterns between rural and urban areas in order to
tailor ring vaccination to specific locations.
Clinical trials are underway to evaluate Ebola vaccine candidates, but there is currently con-
siderable uncertainty regarding the efficacy post-exposure and prophylactically. Our analysis
of vaccine efficacy, ranging between 5–100%, demonstrates a diminishing marginal contribu-
tion with declining vaccine efficacy. For example, at a hypothetical efficacy of 50% ring vacci-
nation could have averted up to 214 cases, whereas a vaccine with an efficacy of 75% up to 360
cases of Ebola could have been averted.
Our modeling approach is based on a deterministic approximation to a stochastic network
model. Consequently, our model did not capture the stochastic effects that become pro-
nounced in the eradication phase of an outbreak [6] and for ring vaccination strategies that in-
clude second-order ring vaccination, where contacts of exposed individuals are vaccinated in
addition to the exposed contacts of the isolated case. We would expect an increase in the mar-
ginal benefit of ring vaccination if both first-order and second-order vaccination were imple-
mented because vaccination would be administered ahead of the wave of transmission. Thus,
our results are conservative with regard to second-order ring vaccination.
Harnessing Case Isolation and Ring Vaccination to Control Ebola
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Ebola has similar family and household transmission as smallpox. During the final eradica-
tion phase of smallpox, public health authorities relied on case isolation and ring vaccination
[18, 19, 47, 48]. Because smallpox is more infectious than Ebola [2, 49, 50], we conservatively
expect that case isolation and ring vaccination would likewise be a practical approach to elimi-
nate Ebola and contain future outbreaks, especially with limited vaccine supplies.
The combined implementation of ring vaccination and case isolation can be an effective ap-
proach in curtailing an Ebola outbreak. Our model predicts that ring vaccination offers moder-
ate benefit to case isolation, with the greatest benefit occurring where there are more contacts
per individual or greater clustering among individuals, and when contact tracing has low effica-
cy or vaccination can confer post-exposure protection.
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S1 Text. Model description and equations.
(PDF)
S2 Text. Extension of sensitivity analysis regarding mixing patterns and vaccine character-
istics.
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S1 Fig. The estimated weekly confirmed incidence for (left column) Liberia and (right col-
umn) Sierra Leone up to March 8, 2015 (black line) for A)-B) k = 5.74 and ϕ = 0.21, C)-D)
k = 5.74 and ϕ = 0.10, E)-F) k = 5.74 and ϕ = 0.40, and G)-H) k = 10 and ϕ = 0.21. The
model was fit to confirmed incidence data (black dots) from June 8, 2014 to January 4, 2015 for
Liberia and May 11, 2014 to January 4, 2015 for Sierra Leone. We forecasted confirmed inci-
dence until March 8, 2015 (red points). For each fit, we calculated the correlation fit value (R2)
for the fitted portion (black) and the forecasted portion (red) of the data.
(TIFF)
S2 Fig. The estimated marginal benefit of adding ring vaccination to case isolation for vari-
ous efficacies of contact tracing and the vaccine in A)-B) Liberia and C)-D)Sierra Leone.
The model was fit using A), C) k = 5.74 and B), D) k = 10, with a clustering coefficient of ϕ =
0.21. A vaccine efficacy of zero would correspond to the implementation of case isolation only.
The marginal benefit was calculated from the initiation of intervention scale up to the end of
the epidemic.
(TIFF)
S3 Fig. The estimated marginal benefit of adding ring vaccination to case isolation for vari-
ous efficacies of contact tracing and the vaccine in A) Liberia and B)Sierra Leone for a vac-
cine that confers post-exposure protection. The model was fit using k = 5.74 with a clustering
coefficient of ϕ = 0.21. A vaccine efficacy of zero would correspond to the implementation of
case isolation only. The marginal benefit was calculated from the initiation of intervention
scale up to the end of the epidemic.
(TIFF)
S4 Fig. The estimated number of symptomatic cases identified through contact tracing as a
result of adding ring vaccination for various efficacies of contact tracing and the vaccine in
A)-B) Liberia and C)-D) Sierra Leone using (A), C)) a prophylactic vaccine and (B), D)) a
vaccine that confers post-exposure protection. A vaccine efficacy of zero would correspond
to the implementation of case isolation only. The model was fit using k = 5.74 and with a clus-
tering coefficient of ϕ = 0.21.
(TIFF)
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S5 Fig. The estimated marginal benefit of adding ring vaccination to case isolation for vari-
ous efficacies of contact tracing and the vaccine in A)-C) Liberia and D)-F) Sierra Leone.
The model was fit using k = 5.74 with a clustering coefficient of A), D) ϕ = 0.10, B), E) ϕ = 0.21,
and C), F) ϕ = 0.40. A vaccine efficacy of zero would correspond to the implementation of case
isolation only. The marginal benefit was calculated from the initiation of intervention scale up
to the end of the epidemic.
(TIFF)
S6 Fig. The estimated marginal benefit of increasing the efficacy of contact tracing and of
the vaccine in A)-B) Liberia and C)-D) Sierra Leone. The model was fit using A), C) k = 5.74
and B), D) k = 10, with a clustering coefficient of ϕ = 0.21. A vaccine efficacy of zero would cor-
respond to the implementation of case isolation only. The marginal benefit was calculated
from the initiation of intervention scale up to the end of the epidemic.
(TIFF)
S7 Fig. The estimated marginal benefit of increasing the efficacy of contact tracing and of
the vaccine in A)-C) Liberia and D)-F) Sierra Leone. The model was fit using k = 5.74 with a
clustering coefficient of A), D) ϕ = 0.10, B), E) ϕ = 0.21, and C), F) ϕ = 0.40. A vaccine efficacy
of zero would correspond to the implementation of case isolation only. The marginal benefit
was calculated from the initiation of intervention scale up to the end of the epidemic.
(TIFF)
S8 Fig. The estimated total number of confirmed cases for various contact tracing and vac-
cine efficacies in A)-B) Liberia and C)-D) Sierra Leone. The model was fit using A), C)
k = 5.74 and B), D) k = 10, with a clustering coefficient of ϕ = 0.21. A vaccine efficacy of zero
would correspond to the implementation of case isolation only.
(TIFF)
S9 Fig. The estimated number of symptomatic cases identified through contact tracing as a
result of adding ring vaccination for various efficacies of contact tracing and the vaccine in
A)-B) Liberia and C)-D) Sierra Leone. The model was fit using A), C) k = 5.74 and B), D)
k = 10, with a clustering coefficient of ϕ = 0.21. A vaccine efficacy of zero would correspond to
the implementation of case isolation only.
(TIFF)
S10 Fig. The estimated total number of confirmed cases for various contact tracing and
vaccine efficacies in A)-C) Liberia and D)-F) Sierra Leone. The model was fit using k = 5.74
with a clustering coefficient of A), D) ϕ = 0.10, B), E) ϕ = 0.21, and C), F) ϕ = 0.40. A vaccine ef-
ficacy of zero would correspond to the implementation of case isolation only.
(TIFF)
S11 Fig. The estimated number of symptomatic cases identified through contact tracing as
a result of adding ring vaccination for various efficacies of contact tracing and the vaccine
in A)-C) Liberia and D)-F) Sierra Leone using (A), C)). The model was fit using k = 5.74 with
a clustering coefficient of A), D) ϕ = 0.10, B), E) ϕ = 0.21, and C), F) ϕ = 0.40. A vaccine efficacy
of zero would correspond to the implementation of case isolation only.
(TIFF)
S1 Table. Estimated parameters for the dynamic model. Using confirmed incidence data for
Liberia and Sierra Leone, we estimated the rate of transmission per infectious contact (β), the
date of Ebola emergence into the population (t0), the initiation of intervention scale up (tS),
and reduced transmission mediated by factors other than intervention (ξ) for a given average
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number of contacts (k) and clustering coefficient (ϕ). For each scenario we provide the basic re-
productive number (R0), the mean square error (MSE), and the correlation fit value for both
the fitted portion (R2) and the forecasted portion (R2F) of the epidemic trajectory.
(TIFF)
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